Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Today’s NR

<< Previous

Bullboard Posts

Next >>

Comment by HCallahann44on Aug 06, 2021 10:02am

166 Views

Post# 33662959

RE:Today’s NR

And the news release was basically NO news....I guess we are in a world no where no news is good news. And they really put a positive spin on those pancreatic results...which really showed little. My only hope is that they are working with patients with trashed immune systems...lets recruit some patients who never had radiation or chemo...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China